Organon (OGN) Q4 2024 earnings summary

Executive summary

• 2024 revenue reached $6.4 billion, up 3% at constant currency, with all major franchises growing and Women's Health and biosimilars as key drivers.

• Adjusted EBITDA was $1.96 billion (30.6% margin), including $81 million of IPR&D expense.

• Diluted EPS was $3.33; adjusted diluted EPS was $4.11.

• Free cash flow before one-time costs was $967 million in 2024; after one-time costs, $617 million.

• Strategic focus on cost savings, capital allocation, and growth from new launches and business development.

Financial highlights

• Adjusted gross margin for 2024 was 61.6%, down from 62.7% in 2023 due to price and inflation impacts.

• Non-GAAP adjusted net income was $1,065 million, nearly flat year-over-year.

• Net leverage ratio ended 2024 at 4.2x, with cash and equivalents at $675 million and gross debt at $8.9 billion.

• Operating expenses increased 1% year-over-year; active net working capital management noted.

• Significant one-time costs in 2024 included $87 million in restructuring and $60 million in supply agreement exits.

Outlook and guidance

• 2025 revenue guidance: $6.125–$6.325 billion, with a $200 million FX headwind and flat to modest constant currency performance.

• Adjusted EBITDA margin guidance for 2025: 31%–32%, maintaining a 31% floor ex-IPR&D.

• Adjusted gross margin expected at 60%–61% in 2025, reflecting continued pricing and cost pressures.

• Volume growth projected at 6%–8%, led by Nexplanon, Vtama, Emgality, and Hadlima.

• $200 million in OpEx savings targeted for 2025, annualizing to $275 million in 2026.